A Study to Describe the Immunogenicity, Safety, and Tolerability of Neisseria Meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Subjects Aged ≥24 Months to <10 Years
NCT02531698
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
1. Evidence of a personally signed and dated informed consent document (ICD) indicating that the subject's parent(s)/legal guardian has been informed of all pertinent aspects of the study. 2. Parent(s)/legal guardian and subject who are willing and able to comply with scheduled visits, vaccine regimen, laboratory tests, and other study procedures. 3. Male or female subjects aged ≥24 months and <10 years at time of randomization, stratified equally by age (≥24 months to <4 years or ≥4 years to <10 years). 4. Subject is available for the entire study period and subject's parent(s)/legal guardian can be reached by telephone. 5. Healthy subject as determined by medical history, physical examination, and judgment of the investigator. 6. Subject must have received all vaccinations in the relevant national immunization program (NIP) for their age group. 7. Male and female subjects of childbearing potential and at risk for pregnancy must agree to use a highly effective method of contraception throughout the study. A subject is of childbearing potential if, in the opinion of the investigator, he/she is biologically capable of having children and is sexually active. 8. Negative urine pregnancy test for all female subjects who are biologically capable of having children.
1. Previous vaccination with any meningococcal serogroup B vaccine.
2. Subjects who have received prior HAV vaccination.
3. Contraindication to vaccination with any HAV vaccine or known latex allergy.
4. Subjects receiving any allergen immunotherapy with a nonlicensed product or subjects
receiving allergen immunotherapy with a licensed product and who are not on stable
maintenance doses.
5. A previous anaphylactic reaction to any vaccine or vaccine-related component.
6. Bleeding diathesis or condition associated with prolonged bleeding time that would
contraindicate intramuscular injection.
7. A known or suspected defect of the immune system that would prevent an immune response
to the vaccine, such as subjects with congenital or acquired defects in B-cell
function, those receiving chronic systemic (oral, intravenous, or intramuscular)
corticosteroid therapy, or those receiving immunosuppressive therapy. Subjects with
terminal complement deficiency may be included. Additional details will be provided in
the study reference manual (SRM).
8. History of microbiologically proven disease caused by N meningitidis or Neisseria
gonorrhoeae.
9. Significant neurological disorder or history of seizure (excluding simple febrile
seizure).
10. Receipt of any blood products, including immunoglobulin, within 6 months before the
first study vaccination.
11. Current chronic use of systemic antibiotics.
12. Participation in other studies involving investigational product(s)/device(s) (Phases
1-4) within 28 days before administration of the first study vaccination.
Participation in purely observational studies is acceptable.
13. Any neuroinflammatory or autoimmune condition, including but not limited to transverse
myelitis, uveitis, optic neuritis, and multiple sclerosis.
14. Other severe acute or chronic medical or psychiatric condition or laboratory
abnormality that may increase the risk associated with study participation or
investigational product administration or may interfere with the interpretation of
study results and, in the judgment of the investigator, would make the subject
inappropriate for entry into this study.
15. Pregnant female subjects, breastfeeding female subjects, male subjects with partners
who are currently pregnant, or male and female subjects of childbearing potential who
are unwilling or unable to use a highly effective method of contraception as outlined
in this protocol for the duration of the study.
16. Subjects who are children of investigational site staff members directly involved in
the conduct of the study and their family members, subjects who are children of site
staff members otherwise supervised by the investigator, or subjects who are children
of Pfizer employees directly involved in the conduct of the study.
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Chandler, Arizona
- Chandler, Arizona
- Huntington Beach, California
- Paramount, California
- San Diego, California
- Valley Village, California
- Tampa, Florida
- Tampa, Florida
- Dalton, Georgia
- Marietta, Georgia
- Woodstock, Georgia
- Meridian, Idaho
- Council Bluffs, Iowa
- Augusta, Kansas
- Bardstown, Kentucky
- Louisville, Kentucky
- Louisville, Kentucky
- Louisville, Kentucky
- Stevensville, Michigan
- Kansas City, Missouri
- Fremont, Nebraska
- Lincoln, Nebraska
- Omaha, Nebraska
- Henderson, Nevada
- Cleveland, Ohio
- Dayton, Ohio
- Dayton, Ohio
- Houston, Texas
- Salt Lake City, Utah
- Salt Lake City, Utah
- Salt Lake City, Utah
- South Jordan, Utah
- West Jordan, Utah
- Vancouver, Washington
- Monroe, Wisconsin
- Monroe, Wisconsin
- Holice,
- Hradec Kralove,
- Hradec Kralove,
- Hradec Kralove,
- Jindrichuv Hradec,
- Odolena Voda,
- Pardubice,
- Pardubice,
- Praha - Nusle,
- Praha 6,
- Sezemice,
- Aarhus N,
- Jarvenpaa,
- Pori,
- Tampere,
- Turku,
- Bad Saulgau,
- Bramsche,
- Eskilstuna,
- Malmo,
- Espoo,
- Helsinki,
- Oulu,
- Pori,
- Tampere,
- Turku,
- Turku,
- Debica,
- Kielczow,
- Krakow,
- Krakow,
- Leczna,
- Poznan,
- Siemianowice Slaskie,
- Wroclaw,
Descriptive Information | ||||
---|---|---|---|---|
Brief Title ICMJE | A Study to Describe the Immunogenicity, Safety, and Tolerability of Neisseria Meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Subjects Aged ?24 Months to <10 Years | |||
Official Title ICMJE | A Phase 2, Randomized, Controlled, Observer-blinded Study To Describe The Immunogenicity, Safety, And Tolerability Of Neisseria Meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine (Bivalent Rlp2086) In Healthy Subjects Aged >/= 24 Months To <10 Years | |||
Brief Summary | This study is looking at a new vaccine that might prevent meningococcal disease, and will study the immune response elicited by this vaccine when given to healthy young children. The study will also look at the safety of the new vaccine as well as how it is tolerated. | |||
Detailed Description | Not Provided | |||
Study Type ICMJE | Interventional | |||
Study Phase ICMJE | Phase 2 | |||
Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Triple (Participant, Care Provider, Investigator) Primary Purpose: Prevention | |||
Condition ICMJE | MENINGOCOCCAL INFECTION | |||
Intervention ICMJE |
| |||
Study Arms ICMJE |
| |||
Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
Recruitment Information | ||||
Recruitment Status ICMJE | Completed | |||
Actual Enrollment ICMJE | 400 | |||
Original Estimated Enrollment ICMJE | Same as current | |||
Actual Study Completion Date ICMJE | March 2017 | |||
Actual Primary Completion Date | March 2017 (Final data collection date for primary outcome measure) | |||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| |||
Sex/Gender ICMJE |
| |||
Ages ICMJE | 24 Months to 10 Years (Child) | |||
Accepts Healthy Volunteers ICMJE | Yes | |||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries ICMJE | Finland, Poland | |||
Removed Location Countries | ||||
Administrative Information | ||||
NCT Number ICMJE | NCT02531698 | |||
Other Study ID Numbers ICMJE | B1971017 2014-000933-21 ( EudraCT Number ) 6108K2-3012 ( Other Identifier: Alias Study Number ) | |||
Has Data Monitoring Committee | Yes | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement ICMJE | Not Provided | |||
Responsible Party | Pfizer | |||
Study Sponsor ICMJE | Pfizer | |||
Collaborators ICMJE | Not Provided | |||
Investigators ICMJE |
| |||
PRS Account | Pfizer | |||
Verification Date | October 2020 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |